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Abstract
Background: Adrenomedullin (AM) is known to be elevated in different clinical situations including diabetes
mellitus (DM), but its potential role in the pathogenesis of vascular complications in diabetic children and
adolescents is to be clarified. Hence, the study aimed at assessment of plasma adrenomedullin levels in children
and adolescents with type 1 DM and correlation of these levels with metabolic control and diabetic microvascular
complications (MVC).
Methods: The study was performed in the Diabetes Specialized Clinic, Children’s Hospital of Ain Shams University
in Cairo, Egypt. It included 55 diabetic children and adolescents (mean age 13.93 ± 3.15 years) who were
subdivided into 40 with no MVC and 15 with MVC. Thirty healthy subjects, age-and sex- matched were included as
control group (mean age 12.83 ± 2.82 years). Patients and controls were assessed for glycosylated hemoglobin
(HbA1c) and plasma adrenomedullin assay using ELISA technique.
Results: Mean plasma AM levels were significantly increased in patients with and without MVC compared to
control group, (110.6 pg/mL, 60.25 pg/mL and 39.2 pg/mL respectively) (P < 0.01) with higher levels in those with
MVC (P < 0.05). Plasma AM levels were positively correlated with both duration of diabetes (r = 0.703, P < 0.001)
and glycemic control (HbA1c) (r = 0.453, P < 0.001).
Conclusion: Higher plasma AM levels in diabetics particularly in those with MVC & its correlation with diabetes
duration and metabolic control may reflect the role of AM in diabetic vasculopathy in the pediatric age group.
Background
Adrenomedullin (AM), a ubiquitous regulatory peptide
with different actions, is expressed in many tissues
throughout the body including the adrenal medulla,
endothelial [1] and vascular smooth muscle cells [2],
myocardium and central nervous system [3,4]. Adreno-
medullin (AM) is widely synthesized and secreted from
most of the cells in the body [5]. It controls prolifera-
tion, differentiation and migration of cells [6]. Adreno-
medullin (AM) is able to act as an autocrine, paracrine,
or endocrine mediator in a number of biologically sig-
nificant functions [7]. It plays a critical role in several
diseases such as cancer, diabetes, cardiovascular and
renal disorders [8,9]. It has vasodilator and blood
pressure lowering properties and plays important role in
maintaining electrolyte and fluid homeostasis [10].
Endogenous AM may protect from organ damage by
inhibiting oxidative stress production [11] and raised
AM levels correlated with increased oxidative stress
[12]. Moreover, evidence that AM possesses a clear cut
proangiogenic effect under both physiological and
pathophysiological conditions has accumulated [13-15].
Adrenomedullin is involved in insulin regulatory system
[16-18] and is elevated in plasma from patients with
pancreatic dysfunctions such as type 1 or type 2 diabetes
and insulinoma [18]. Adrenomedullin might play a role
in the pathogenesis of diabetic vasculopathy in type 1
[19] and type 2 diabetes [20]. However, to the best of
our knowledge, there is no published data about AM
level in type 1 diabetic children and adolescents. Hence,
this study aimed at assessment of plasma adrenomedul-
lin levels in type 1 diabetic children and adolescents and
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Materials and methods
Subjects
This case control study included 55 consecutive type 1
diabetic children and adolescents recruited from Diabe-
tology Clinic, Children’s Hospital, Ain Shams University,
Cairo, Egypt during the period from May 2004 to May
2006. Those with liver disease, renal failure or conges-
tive heart failure were excluded [19]. According to the
presence or absence of MVC, patients were classified
into: Group 1: 40 diabetic patients without MVC. Group
2 comprised 15 diabetic patients with MVC (retinopa-
thy, neuropathy and/or nephropathy). Thirty apparently
healthy age and sex matched children and adolescents
were included as a control group. Informed consent was
obtained from patients’ parents or their legal guardians
after study approval by the Local Ethical Committee,
Ain Shams University (FWA00006444).
Methods
Patients were subjected to careful history taking laying
stress on onset, duration, frequency of diabetic ketoaci-
dosis (DKA) or hyperglycemic attacks, thorough clinical
examination with special emphasis on signs of diabetic
complications. Fundus examination was performed by
an ophthalmologist after maximum papillary dilatation
using indirect ophthalmoscope to identify diabetic reti-
nopathic changes [21].
Laboratory investigations
Assessment of glycemic control by calculating the mean
glycosylated hemoglobin (HbA1c) over the last year was
performed using high performance liquid chromatogra-
phy (HPLC) technique [22]. Patients were considered
under optimal glycemic control when their HbA1c was
< 7.5% [23]. Microalbuminuria was assayed using SERA-
PAK immuno-microalbumin Kit (Bayer Corporation,
Benedict Ave, Tarry town, NY, USA). Persistent micro-
albuminuria was defined when two of three samples
showed urinary albumin excretion rate of 30-300 μg/mg
creatinine [24]. Two ml of venous blood were collected
on EDTA tube, centrifuged for 15 minutes and plasma
samples were stored at -70°C till assay. Plasma adreno-
medullin level was assessed by ELISA technique using
adrenomedullin (human) (EIA-3418) kit, DRG interna-
tional Inc., USA).
Statistical Analysis
Analysis of data was performed by using SPSS (version
15). Comparison between 2 groups of patients was
made using Student’s t-test for parametric measures and
Wilcoxon signed-rank test (Z value) for non parametric
measures. Spearman’s rank correlation coefficient was
used to correlate between two quantitative variables. P
value < 0.05 was considered the cut-off value for
significance.
Results
Diabetic patients (n = 55) and controls were comparable
as regards age, gender and BMI. Age, duration of dia-
betes and mean HbA1c were significantly higher in
patients with MVC (n = 15) compared to patients with-
out MVC (n = 40) (P < 0.01, P < 0.01, P < 0.05 respec-
tively) and to controls (Table 1). Compared to healthy
subjects, each patients’ group displayed significantly
increased AM levels (P < 0.05), with higher values in
diabetics with MVC than those without (P < 0.05)
(Table 1, Table 2). Significant positive correlation
between AM levels and both duration of diabetes (r =
0.703, P < 0.001) and HbA1c (r = 0.453, P < 0.001) was
observed among diabetic patients (n = 55) with a non
significant correlation with age (r = 0.09, P = 0.51).
Discussion
In the present study, diabetic patients showed highly sig-
nificant increase in plasma AM levels compared to con-
trols. These results are in agreement with Hayashi et al
[25] who reported significant increase in plasma AM in
hyperglycemic patients compared with normal volun-
teers. However, Kinoshita et al. [26] found that when
patients with nephropathy were excluded, plasma levels
of AM were not significantly different in old diabetic
patients and healthy individuals.
Our patients with MVC displayed higher AM levels
compared to those without. Similar results were
reported in other studies [19,20,27]. Yet, they reported
no significant difference in patients with nephropathy,
neuropathy or retinopathy (P > 0.05). In the current
study, highest AM levels were observed in diabetic
patients with retinopathy and nephropathy. Higher
plasma AM levels in our diabetic patients with microal-
buminuria compared to normoalbuminuric patients dif-
fers from Garcia-Unzueta et al [19] who reported higher
levels of AM and cAMP in patients with renal insuffi-
ciency but normal in microalbuminuric patients.
Furthermore, adult type 1 diabetic patients with renal
insufficiency had higher levels of plasma AM than dia-
betics with other complications, and plasma AM
increase was proportionate to kidney function deteriora-
tion [19]. Adrenomedullin could exert a wide range of
vascular actions (mostly protective). These include
endothelium-dependent and -independent vasodilata-
tion, antioxidative stress, stimulation of endothelial
nitric oxide production, antiproliferation of vascular
smooth muscle cell, and adventitial fibroblast[28]. Taken
together, the elevation of plasma adrenomedullin level
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pathy) could participate in the mechanism against pro-
gression of vascular damage [28].
Highest individual plasma AM values recorded in our
diabetics with retinopathy are similar to previous studies
[19,29]. Adrenomedullin may also play a role in the neo-
vascularization process that occurs after retinal ischemia.
Increased AM levels in vitreous humor of patients with
proliferative vitreoretinopathy [30,31] and diabetic reti-
nopathy [32] suggested the involvement of AM as a pos-
sible associated factor in the course of vascular and
proliferative retinal diseases.
Increased AM levels with longer duration of diabetes
is consistent with Garcia-Unzueta et al. [19] who
reported similar relationship suggesting that the eleva-
tion of AM levels is a late phenomenon due to endothe-
lial dysfunction. Also, there was a significant correlation
between AM levels and HbA1c with higher HbA1c
levels among diabetics with MVC. Similarly, Caliumi et
al. [33] reported that increased circulating AM corre-
lates with poor glucose metabolic control in type 2 dia-
betics. The elevated plasma AM level originates from
vascular AM expression induced by hyperglycemia
through protein kinase C-dependent pathway [34].
Our patients with MVC displaying higher AM levels
were older than those without. However, no significant
correlation was observed between AM and age. Simi-
larly, Hayashi et al [25] reported no change in AM levels
with age. Older age, longer duration of diabetes and
puberty are known risk factors for MVC [35]. It is still
uncertain whether increased release of AM in diabetes
is a compensatory mechanism or a coincident event.
The precise role of AM in the pathogenesis of diabetic
complications is still to be elucidated [36].
Conclusions
The increase in plasma adrenomedullin level in type 1
diabetic children and adolescents being correlated with
disease duration and metabolic control; the two most
independent risk factors for the occurrence of MVC;
may declare its role in the pathogenesis of diabetic
microangiopathy since childhood.
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Table 1 Comparison between diabetic patients with and without MVC and controls as regards age, disease duration
and laboratory findings.
Variable Tests Group 1 Patients with
MVC (N = 15)
Group 2 Patients without
MVC(N = 40)
Controls (N = 30)
Male/Female 7/8 26/14 17/13
Mean ± SD Mean ± SD Mean ± SD P
Age (yrs) 17.13 ± 1.5 12.73 ± 2.7 12.83 ± 2.4 P1 < 0.001, P2 < 0.001, P3 > 0.05*
BMI(Kg/m2) 21.39 ± 3.25 23.27 ± 3.8 22.11 ± 3.23 P > 0.05*
Systolic BP percentile 70.48 ± 21.7 66.4 ± 26.4 67.5 ± 23.23 P > 0.05*
Diastolic BP percentile 68.84 ± 13.6 64.7 ± 19.8 66 ± 18.3 P > 0.05*
Duration of diabetes (yrs) 9.6 ± 3.3 3.8 ± 3.8 - P < 0.001*
HbA1c (%) 9.36 ± 1.8 8.09 ± 2.02 4.2 ± 0.4 P < 0.05*
AM (pg/mL) 110.6 ± 94.24 60.25 ± 31.76 39.2 ± 12.43 Z1-2.01, Z2-2.7, Z3-3.37
P1 = 0.04, P2 < 0.01, P3 = 0.001#
SD, standard deviation; BMI, body mass index;*Student t test; # Wilcoxon signed-rank test (Z value), Z1, P1 between groups 1&2; Z2, P2 between groups 1 &
controls; Z3, P3 between group 2 & controls.
Table 2 Median plasma adrenomedullin levels in patients
with and without diabetic microangiopathy and control
group
Group N Median AM(pg/ml) Confidence
interval*
Nephropathy 15 75 58.41-162.79
Nephropathy +
retinopathy
5 200 23.02-348.98
Nephropathy +
neuropathy
37 0
Without MVC 40 65 50.22 - 70.28
Controls 30 40 34.64 - 43.76
*95
th confidence interval
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